Your browser doesn't support javascript.
loading
Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
Ren, Hongye; Berry, Sasha; Malkin, Samuel Joseph Paul; Hunt, Barnaby; Bain, Stephen.
Affiliation
  • Ren H; External Affairs, Diabetes & CV, Novo Nordisk Denmark A/S, Copenhagen, Denmark.
  • Berry S; Market Access, Novo Nordisk Ltd, Gatwick, UK.
  • Malkin SJP; Ossian Health Economics and Communications GmbH, Basel, Switzerland malkin@ossianconsulting.com.
  • Hunt B; Ossian Health Economics and Communications GmbH, Basel, Switzerland.
  • Bain S; Swansea University Medical School, Swansea, UK.
BMJ Open ; 13(9): e070473, 2023 09 29.
Article in En | MEDLINE | ID: mdl-37775297
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Complications / Diabetes Mellitus, Type 2 / Insulins / Sodium-Glucose Transporter 2 Inhibitors / Metformin Type of study: Clinical_trials / Health_economic_evaluation Aspects: Patient_preference Limits: Humans Country/Region as subject: Europa Language: En Journal: BMJ Open Year: 2023 Document type: Article Affiliation country: Denmark Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Complications / Diabetes Mellitus, Type 2 / Insulins / Sodium-Glucose Transporter 2 Inhibitors / Metformin Type of study: Clinical_trials / Health_economic_evaluation Aspects: Patient_preference Limits: Humans Country/Region as subject: Europa Language: En Journal: BMJ Open Year: 2023 Document type: Article Affiliation country: Denmark Country of publication: United kingdom